Загрузка...
OP17. Measuring and modifying Temozolomide delivery in brain tumours
INTRODUCTION: Malignant brain tumours constitute a fatal diagnosis with 5-year survival rates of less than 5%. Temozolomide (TMZ) is the central chemotherapy agent used in the treatment of malignant brain tumours; however, despite aggressive treatment approaches outcomes are still poor with many pat...
Сохранить в:
| Опубликовано в: : | Neuro Oncol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5358586/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now292.016 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|